AMENDMENTS TO THE CEATMS

Claims 1-19 (Cancelled)

Claim 20 (Currently Amended) A process for producing a compound represented by the general formula [I-1]:

fin in which A^a stands for a group of the formula [a₀]

$$N$$
 R^{60}
 $[a_0]$

Ar¹, Ar² and Ar³ each independtly independently stands for optionally substituted phenyl, the substituent being selected from the group consisting of halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, carbamoyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl; R¹ stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl;

R², R³, R⁴ and R⁵ each independently stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl, or R² and R³, or R⁴ and R⁵, may together stand for, independently of each other, optionally substituted trimethylene, propenylene, tetramethylene or 2-butenylene group, the substituent being selected from the group consisting of oxo, hydroxyl, amino, lower alkoxy, lower alkanoyloxy, lower alkylamino, di-lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower

alkylcarbamoyl, di-lower alkylcarbamoyl, imidazolyl and a group represented by $-R^7$, R^7 standing for optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkoxycarbonyl and imidazolyl; R^{60} stands for hydrogen, C_1 - C_{10} alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl; and k, m, n, s, X and Y have later defined significations significations

or salts thereof, which comprises reacting carboxylic acid of the general formula [II]:

$$Ar^{1p} \xrightarrow{Ar^{2p}} CH - C - OH$$
 [II]

[in in which Ar^{1p}, Ar^{2p} and Ar^{3p} each independently stands for optionally substituted phenyl, the substituent being selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkoxy and di-lower alkylcarbamoyl and optionally protected hydroxyl, carbamoyl and lower alkylcarbamoyl; and R^{1p} stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of di-lower alkylcarbamoyl, optionally protected hydroxyl, amino, carbamoyl, lower alkylcarbamoyl and imidazolyl groups] groups

or salt or reactive derivative thereof with a compound of the general formula [III]:

$$R^{2p}R^{3p}$$
 $R^{4p}R^{5p}$ O | | | | | | H HN-CH-(CH₂)_k-X-Y-CH-(CH₂)_m-C-N-(CH₂)_n---A^{ap} [III]

 \varprojlim in which A^{ap} stands for a group of the formula $[a_{op}]$

$$\frac{1}{2} \sum_{s}^{N} R^{60p} \left[a_{0p} \right]$$

k means 0 or 1; m, n and s each independently means 0, 1 or 2; R^{2p}, R^{3p}, R^{4p} and R^{5p} each independently stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of di-lower alkylcarbamoyl and optionally protected hydroxyl, amino, carbamoyl, lower alkylcarbamovl and imidazolyl groups, or R^{2p} and R^{3p}, or R^{4p} and R^{5p}, together form, each independently of the other pair, optionally substituted trimethylene, propenylene, tetramethylene or 2-butenylene, the substituent being selected from the group consisting of lower alkoxy, lower alkanoyloxy, di-lower alkylamino, lower alkoxycarbonyl, di-lower alkylcarbamoyl, a group represented by -R^{7p} and optionally protected oxo, hydroxyl, amino, lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, carbamoyl, lower alkylcarbamoyl and imidazolyl groups; R^{7p} stands for optionally substituted lower alkyl, the substituent being selected from the group consisting of di-lower alkylcarbamoyl and lower alkoxycarbonyl, and optionally protected hydroxyl, amino, carbamovl, lower alkylcarbamovl and imidazolyl groups: R^{60p} stands for imino-protecting group, C₁-C₁₀ alkyl, lower alkenyl, cycloalkyl, cycloalkyllower alkyl whose ring potion being optionally substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl; X stands for carbonyl or methylene; and Y stands for nitrogen or methine methine

or a salt thereof to form a compound represented by the general formula [IV-1]

or a salt thereof, and if necessary removing the protective group(s). Claims 21-24 (Cancelled)

Claim 25 (New) Compounds which are represented by the following general formula [I]

in which A stands for a group of the following formula [a₀]

$$- \underbrace{\begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array}}_{S} R^{60}$$
 [a 0]

Ar¹, Ar² and Ar³ each independently stands for optionally substituted phenyl, the substituent being selected from the group consisting of halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkoxy, carbamoyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl; k means 0 or 1; m and n each independently means 0, 1 or 2; s means 1; R¹ stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl; R², R³, R⁴ and R⁵ each independently stands for hydrogen or optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, dilower alkylcarbamoyl and imidazolyl, or R² and R³, or R⁴ and R⁵, may together stand for, independently of each other, optionally substituted trimethylene, propenylene, tetramethylene or 2-butenylene group, the substituent being selected from the group consisting of oxo, hydroxyl, amino, lower alkoxy, lower alkanoyloxy, lower alkylamino, di-lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, imidazolyl and a group represented by $-R^7$, R^7 standing for optionally

substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkoxycarbonyl and imidazolyl; R⁶⁰ stands for hydrogen, C₁-C₁₀ alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl; X stands for carbonyl or methylene; and Y stands for nitrogen or methane or salts thereof.

Claim 26 (New) The compounds according to Claim 25, in which Ar¹, Ar² and Ar³ each independently stands for phenyl which is optionally substituted with halogen or lower alkyl; n is 1 or 2; s is 1; and R¹ is hydrogen.

Claim 27 (New) The compounds according to Claim 26, which are represented by the general formula [I-a]:

$$R^{8} \longrightarrow CH_{2}-C-N-CH-C-N-(CH_{2})_{2}-C-N-CH_{2}-A^{1} \qquad [I-a]$$

wherein A¹ stands for a group represented by the formula [a₁]

$$\mathbb{R}^{60}$$
 [a 1]

R^{2a} and R^{3a} each independently stands for hydrogen, or optionally substituted lower alkyl, the substituent being selected from hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl and imidazolyl; R⁸ stands for hydrogen, halogen or lower alkyl; and R⁶⁰ stands for hydrogen, C₁-C₁₀ alkyl,

lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 28 (New) The compounds according to Claim 26, which are represented by the general formula [I-b]:

wherein A^{1a} stands for a group of the formula [a₁]

 R^8 stands for hydrogen, halogen or lower alkyl; and R^{60} stands for hydrogen, C_1 - C_{10} alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 29 (New) The compounds according to Claim 26, which are represented by the general formula [I-c]:

in which A¹ stands for a group represented by the formula [a₁]

 R^8 stands for hydrogen, halogen or lower alkyl; and R^{60} stands for hydrogen, C_1 - C_{10} alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 30 (New) The compounds according to Claim 26, which are represented by the general formula [I-d]

$$R^{8}$$
 CH_{2}
 CH_{2}

in which A^{1a} stands for a group of the formula $[a_1]$

$$N$$
 R^{60} $[a_1]$

R⁸ stands for hydrogen, halogen or lower alkyl; R⁶⁰ stands for hydrogen, C₁-C₁₀ alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 31 (New) The compounds according to Claim 26, which are represented by the general formula [I-e]

$$R^{8} \xrightarrow{R^{e1}} CH_{2}^{e2} C - N - CH - C - N - CH - C - N - (CH_{2})_{n1} - A^{1} \qquad [\text{ I-e }]$$

in which A¹ stands for a group represented by the formula [a₁]

n1 stands for 1 or 2; R^{e1}, R^{e2}, R^{e3} and R^{e4} each independently stands for hydrogen, hydroxyl, amino, lower alkoxy, lower alkanoyloxy, lower alkylamino, di-lower alkylamino, (imino-lower alkyl)amino, lower alkanoylamino, lower alkoxycarbonylamino, (lower alkylcarbamoyl)amino, lower alkylsulfonylamino, guanidino, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, imidazolyl and a group represented by –R⁷; or R^{e1} and R^{e2} together signify oxo group; R⁷ stands for optionally substituted lower alkyl, the substituent being selected from the group consisting of hydroxyl, amino, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkoxycarbonyl and imidazolyl; R⁸ stands for hydrogen, halogen or lower alkyl; and R⁶⁰ stands for hydrogen, C₁-C₁₀ alkyl, lower alkenyl, cycloalkyl, cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl, cycloalkenyl-lower alkyl or aralkyl.

Claim 32 (New) The compounds according to Claim 31, in which R^{e1} is hydrogen or hydroxyl, and all of R^{e2}, R^{e3} and R^{e4} are hydrogen.

Claim 33 (New) The compounds according to any one of claims 25 to 32, in which R^{60} is hydrogen, C_1 - C_{10} alkyl, cycloalkyl or cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl.

Claim 34 (New) The compounds according to Claim 33, in which said C₁-C₁₀ alkyl as R⁶⁰ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl, heptyl, octyl or decyl.

Claim 35 (New) The compounds according to Claim 33, in which said cycloalkyl group as R⁶⁰ is cyclopentyl or cyclohexyl.

Claim 36 (New) The compounds according to Claim 33, in which said cycloalkyl-lower alkyl whose ring portion may be substituted with lower alkyl as R⁶⁰ is cyclopropylmethyl, cyclobutylmethyl, 2-(1-methylcyclopropyl)ethyl, cyclopentylmethyl, (2,2-dimethyl-cyclopentyl)methyl, 1-cyclopentylethyl, cyclohexylmethyl or 1-cyclohexylethyl.

Claim 37 (New) A pharmaceutical composition for the treatment of diseases associated with muscarinic M₃ receptors, which comprises a muscarinic M₃ antagonistically effective amount of compound of formula [I] according to Claim 25 or a salt thereof, and a pharmaceutically acceptable adjuvant.

Claim 38 (New) A method for the treatment of chronic obstructive pulmonary diseases, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema and rhinitis; irritable bowel syndrome, convulsive colitis, gastroduodenal ulcer, convulsion or hyperanakinesia of digestive tract, diverticulitis and pain accompanying contraction of smooth muscles of the digestive system; urinary incontinence, urgency and pollakiuria in nervous pollakiuria, neurogenic bladder, nocturnal enuresis, unstable bladder, cystospasm and chronic cystisis; and motion sickness, which comprises administering a muscarinic M₃ antagonistically effective amount of compound of formula [I] according to Claim 25 or a salt thereof to a patient suffering from the diseases.